- Home
- ATO vs BIIB Comparison
ATO vs BIIB Comparison
Compare ATO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATO
- BIIB
- Stock Information
- Founded
- ATO 1906
- BIIB 1978
- Country
- ATO United States
- BIIB United States
- Employees
- ATO N/A
- BIIB N/A
- Industry
- ATO Oil/Gas Transmission
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- ATO Utilities
- BIIB Health Care
- Exchange
- ATO Nasdaq
- BIIB Nasdaq
- Market Cap
- ATO 21.4B
- BIIB 25.1B
- IPO Year
- ATO 1987
- BIIB 1991
- Fundamental
- Price
- ATO $139.77
- BIIB $149.78
- Analyst Decision
- ATO Buy
- BIIB Buy
- Analyst Count
- ATO 9
- BIIB 26
- Target Price
- ATO $144.72
- BIIB $248.00
- AVG Volume (30 Days)
- ATO 842.5K
- BIIB 1.6M
- Earning Date
- ATO 02-04-2025
- BIIB 02-11-2025
- Dividend Yield
- ATO 2.48%
- BIIB N/A
- EPS Growth
- ATO 11.97
- BIIB 10.05
- EPS
- ATO 6.83
- BIIB 11.06
- Revenue
- ATO $4,165,187,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- ATO $19.71
- BIIB N/A
- Revenue Next Year
- ATO $10.13
- BIIB N/A
- P/E Ratio
- ATO $20.51
- BIIB $13.47
- Revenue Growth
- ATO N/A
- BIIB N/A
- 52 Week Low
- ATO $110.46
- BIIB $145.07
- 52 Week High
- ATO $152.65
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- ATO 41.92
- BIIB 31.81
- Support Level
- ATO $136.05
- BIIB $145.07
- Resistance Level
- ATO $140.45
- BIIB $149.92
- Average True Range (ATR)
- ATO 2.43
- BIIB 3.57
- MACD
- ATO -0.30
- BIIB 0.18
- Stochastic Oscillator
- ATO 41.21
- BIIB 22.27
About ATO Atmos Energy Corporation
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.